PDCD1 and hepatocellular carcinoma: We hypothesize that a comprehensive treatment approach combining TACE with lenvatinib and a PD-1 inhibitor (TACE+LEN+PD-1) could serve as a more effective therapeutic strategy for intermediate-stage HCC patients exceeding the up-to-7 criteria.